Thank you for your responses to my last post about Sophie's new medication and my frustrations in getting it added to Anthem's formulary. The drug, called Vimpat or locosamide, is a relatively new anti-epileptic drug.
It is NOT investigational. Like most AEDs, though, it is approved for persons 17 years and older which is, perhaps, the arbitrary glitch that we're encountering. However, many of the drugs approved for use in epilepsy are approved for older children and/or adults and Sophie has been on all of them, no problem.
Second, the consensus overall is that EPILEPSY MEDICATIONS SHOULD NOT BE SWITCHED OR SUBSTITUTED. GENERIC VERSIONS ARE NOT RECOMMENDED. You can read more about that here.
Third, there is no appropriate anti-epileptic drug that Sophie has not already tried. Too many double negatives? Sophie's epilepsy is refractory to medication, meaning that no drug or combination of drugs up to this point has helped her. We can only hope that new drugs, as they become available might do so.
What I am trying to do, with the help of the Epilepsy Foundation of Greater Los Angeles, The Neurologist and the drug company itself, is to educate Anthem about these issues. This sort of thing happens all the time and is extremely detrimental, as you can imagine, for many epilepsy patients. What goes on their formulary of "approved" medications appears to be systematically arbitrary.
I'll keep you posted and thank you, again, for all your support and advice! Keep it coming!